MGMT and supranuclear palsy, progressive, 1: Between patients with true progression and PsP, there were no significant differences in demographic data, histology, MGMT methylation status, KPS, prior chemotherapy, prior immunosuppression therapy, baseline steroid use, treatment regimen (concurrent RT/TMZ versus RT only), adjuvant chemotherapy, presence of infection at baseline and laboratory data (baseline ALC and CD4 count).